CMN Weekly (20 December 2024) - Your Weekly CRISPR...
CMN Weekly
Dec. 20, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
BRL Medicine
Company Type: Therapeutic development
Main focus: Developing breakthrough curative treatments for various human diseases through gene editing
Company stage: Clinical
Diseases: Cancer, autoimmune diseases, and haemoglobinopathies
Genome-editing tool: CRISPR-Cas9
Funding stage: Series B
Location: Minhang District, Shanghai, China
Website: https://www.brlmed.com/en/index.html
Pipeline: https://www.brlmed.com/en/index.html
Partners:
BRL Medicine is a biotechnology company specialising in gene- and cell therapies. The company focuses on developing innovative treatments for genetic diseases, cancer, and immune disorders using advanced gene-editing and gene-modified cell technologies. BRL Medicine’s gene-editing technology innovation platform (CRISTARS®) is dedicated to developing gene-editing tools. The company’s pipeline features several pre-clinical and clinical trials involving both gene therapies and genetically-engineered cell therapies.
